Magellan Asset Management Ltd Buys New Shares in Stryker Corporation $SYK

Magellan Asset Management Ltd acquired a new position in Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 20,099 shares of the medical technology company's stock, valued at approximately $6,328,000.

Several other institutional investors also recently bought and sold shares of the stock. Gables Capital Management Inc. purchased a new position in Stryker in the 2nd quarter worth approximately $25,000. Kilter Group LLC purchased a new stake in shares of Stryker during the second quarter valued at approximately $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the fourth quarter worth approximately $26,000. Sankala Group LLC purchased a new position in shares of Stryker in the fourth quarter worth $26,000. Finally, Compass Financial Management LLC bought a new stake in Stryker during the 2nd quarter valued at $27,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Insider Activity

In other news, insider Debra King sold 826 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the firm's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company's stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 665,370 shares of company stock worth $216,238,501. Insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

SYK has been the topic of a number of recent analyst reports. Piper Sandler cut their price target on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Leerink Partners cut their target price on Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a research note on Friday, June 5th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. Needham & Company LLC reduced their target price on Stryker from $454.00 to $418.00 and set a "buy" rating on the stock in a research note on Friday, May 1st. Finally, BMO Capital Markets initiated coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.

Stryker Stock Up 0.1%

SYK stock opened at $329.86 on Monday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The company has a market capitalization of $126.52 billion, a price-to-earnings ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The business's 50 day moving average price is $326.99 and its two-hundred day moving average price is $332.39. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm's revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source